Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

M. Clarke; A. S. Coates; S. C. Darby; C. Davies; R. D. Gelber; Jon Godwin; A. Goldhirsch; R. Gray

doi:10.1016/S0140-6736(08)60069-0

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

M. Clarke, A. S. Coates, S. C. Darby, C. Davies, R. D. Gelber, Jon Godwin, A. Goldhirsch, R. Gray

Research output: Contribution to journal › Article › peer-review

224 Citations (Scopus)

Abstract

The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).

Original language	English
Pages (from-to)	29-40
Number of pages	12
Journal	Lancet
Volume	371
Issue number	9606
DOIs	https://doi.org/10.1016/S0140-6736(08)60069-0
Publication status	Published - 1 Jan 2008

Keywords

breast cancer
oestrogen receptor
adjuvant therapy
clinical trials
chemotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Documents and Links

10.1016/S0140-6736(08)60069-0

Cite this

@article{a7d7251e0a014db28dd7e8d16dfde088,

title = "Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials",

abstract = "The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).",

keywords = "breast cancer, oestrogen receptor, adjuvant therapy, clinical trials, chemotherapy",

author = "M. Clarke and Coates, {A. S.} and Darby, {S. C.} and C. Davies and Gelber, {R. D.} and Jon Godwin and A. Goldhirsch and R. Gray",

note = "<p>Originally published in: The Lancet (2008), 371 (9609), pp.29-40.</p>",

year = "2008",

month = jan,

day = "1",

doi = "10.1016/S0140-6736(08)60069-0",

language = "English",

volume = "371",

pages = "29--40",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9606",

}

TY - JOUR

T1 - Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

AU - Clarke, M.

AU - Coates, A. S.

AU - Darby, S. C.

AU - Davies, C.

AU - Gelber, R. D.

AU - Godwin, Jon

AU - Goldhirsch, A.

AU - Gray, R.

N1 - <p>Originally published in: The Lancet (2008), 371 (9609), pp.29-40.</p>

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).

AB - The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).

KW - breast cancer

KW - oestrogen receptor

KW - adjuvant therapy

KW - clinical trials

KW - chemotherapy

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-37549055451&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(08)60069-0

DO - 10.1016/S0140-6736(08)60069-0

M3 - Article

VL - 371

SP - 29

EP - 40

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9606

ER -

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

Abstract

Keywords

UN SDGs

Documents and Links

Other files and links

Fingerprint

Cite this